Abstracts tagged "Allopurinol and gout"

Abstract Number: 359 • 2019 ACR/ARP Annual Meeting
Impact of Hospital Admissions on Adherence to Allopurinol Therapy After Discharge
Nicholas Lebedoff¹, Andrea Barker ², Curry L. Koening ³, Trevor Jones ⁴, Richard Rose ⁴, Peter Yarbrough ⁴ and Michael Battistone ⁵, ¹University of Utah, Salt Lake City, ²Salt Lake City Veterans Affairs Medical Center & University of Utah, North Salt Lake, UT, ³University of Utah Hospital, Salt Lake City, UT, ⁴Salt Lake City Veterans Affairs Medical Center & University of Utah, Salt Lake City, ⁵Salt Lake City Veterans Affairs Medical Center & University of Utah, Salt Lake City, UT
Background/Purpose: Gout is a common disease with effective medical therapies, yet many cases are complicated by providers’ hesitancy to prescribe an adequate dose of urate-lowering…
Abstract Number: 2229 • 2018 ACR/ARHP Annual Meeting
Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: The two most common causes of inadequate serum urate (SU) lowering with allopurinol are low adherence and under-dosing. Those who are adherent, but do…
Abstract Number: 2230 • 2018 ACR/ARHP Annual Meeting
Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
Estella Yeo¹, Suetonia Palmer², Peter T. Chapman³, Christopher Frampton⁴ and Lisa K. Stamp⁴, ¹Canterbury District Health Board, Christchurch, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³Christchurch Hospital, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: To explore the number of patients on haemodialysis (HD) or peritoneal dialysis (PD) with gout in Canterbury and to determine how many were receiving…
Abstract Number: 1266 • 2018 ACR/ARHP Annual Meeting
ABCG2 rs2231142 Q141K and Oxypurinol Concentration in People with Gout Receiving Allopurinol
Lisa K. Stamp¹, Mary Wallace², Rebecca Roberts³, Christopher Frampton¹, Jeffrey Miner⁴, Tony R. Merriman³ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴Viscentio Bio, San Diego, CA, ⁵University of Auckland, Auckland, New Zealand
Background/Purpose: Association of ABCG2 Q141K (p.141Lys) with poor urate-lowering response to allopurinol has been reported although the mechanism is unclear. ABCG2 has been reported to…
Abstract Number: 1105 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol at higher than CrCL based doses remains controversial due to concerns over increased risk of adverse events (AE). A recent 12month randomized controlled…
Abstract Number: 1138 • 2017 ACR/ARHP Annual Meeting
Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout
Xiaomin Li¹, Qiujing Wei², Naomi Schlesinger³ and Jieruo Gu², ¹Rheumatology, Third affiliated hospital of Sun Yat-sen University, Guangzhou, China, ²Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Allopurinol, effectively regulates and controls serum uric acid levels but may cause allopurinol-induced life-threating severe cutaneous adverse reaction (SCAR). Previous studies reported that single…
Abstract Number: 3078 • 2015 ACR/ARHP Annual Meeting
ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout
Lisa K. Stamp¹, Mary Wallace², Tony R. Merriman³, Amanda Phipps-Green⁴, Ruth Topless^4,5, Jill Drake⁶, Paul Tan⁷, Nicola Dalbeth⁸ and Rebecca Roberts⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁷University of Auckland, Auckland, New Zealand, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Many patients fail to reach target serum urate (SU) on allopurinol. Although the most common causes of inadequate response are non-adherence and low dosing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].